18:36 , Nov 9, 2018 |  BC Week In Review  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
23:40 , Nov 8, 2018 |  BC Extra  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
16:33 , Apr 20, 2018 |  BC Week In Review  |  Company News

Highmark, AstraZeneca in outcomes-based Symbicort contract

Blue Cross Blue Shield's Highmark Inc. affiliate and AstraZeneca plc (LSE:AZN; NYSE:AZN) entered into an outcomes-based contract for Symbicort budesonide/formoterol to treat symptoms in chronic obstructive pulmonary disease (COPD) and asthma patients in Pennsylvania, West...
23:02 , Apr 17, 2018 |  BC Extra  |  Company News

Highmark, AstraZeneca in outcomes-based Symbicort contract

Blue Cross Blue Shield's Highmark Inc. affiliate and AstraZeneca plc (LSE:AZN; NYSE:AZN) entered into an outcomes-based contract for Symbicort budesonide/formoterol to treat symptoms in chronic obstructive pulmonary disease (COPD) and asthma patients in Pennsylvania, West...
20:27 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

After Phase III results, AZ's COPD combo heading for submissions

AstraZeneca plc (LSE:AZN; NYSE:AZN) said triple combination therapy PT010 met six of seven primary endpoints evaluating lung function in the Phase III KRONOS trial to treat moderate to very severe chronic obstructive pulmonary disease (COPD)....
21:36 , Jan 26, 2018 |  BC Extra  |  Clinical News

After Phase III results, AZ's COPD combo heading for submissions

AstraZeneca plc (LSE:AZN; NYSE:AZN) said triple combination therapy PT010 met six of seven primary endpoints evaluating lung function in the Phase III KRONOS trial to treat moderate to very severe chronic obstructive pulmonary disease. The...
00:32 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

FDA approves Symbicort to reduce COPD exacerbations

In September, FDA approved Symbicort budesonide/formoterol from AstraZeneca plc (LSE:AZN; NYSE:AZN) to reduce exacerbations of chronic obstructive pulmonary disorder (COPD). The combination of budesonide, an inhaled steroid, and formoterol, a long-acting adrenergic receptor beta 2...
22:09 , Sep 19, 2017 |  BC Extra  |  Company News

FDA approves GSK's triple combo for COPD maintenance

FDA approved an NDA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol for maintenance treatment of chronic obstructive pulmonary disease. GSK said Trelegy Ellipta is the first once-daily single inhaler triple therapy approved...
20:52 , Mar 23, 2017 |  BC Week In Review  |  Company News

AZ, Circassia deal

AstraZeneca agreed to share rights to two chronic obstructive pulmonary disease therapies with Circassia. Circassia will lead promotion of AZ's Tudorza Pressair aclidinium bromide in the U.S., and may opt to acquire full U.S. rights....
22:25 , Mar 17, 2017 |  BC Extra  |  Company News

AZ, Circassia to share rights to two COPD therapies

AstraZeneca plc (LSE:AZN; NYSE:AZN) agreed to share rights to two chronic obstructive pulmonary disease therapies with Circassia Pharmaceuticals plc (LSE:CIR). Circassia is to lead promotion of AZ's Tudorza Pressair aclidinium bromide in the U.S., and...